ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers

ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers
The combination of Array BioPharma‘s immunotherapy ARRY-382 and Keytruda (pembrolizumab) has a manageable safety profile and has shown preliminary signs of effectiveness in pancreatic and ovarian cancer patients, a new Phase 1b study shows. The findings were recently presented at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting in National Harbor, Maryland, in a poster titled, “Phase 1b/2

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *